Metraipolis › archive › dc_b2f0e60b80fb

A comparative study on the efficacy and safety of biosimilar (Rimmyrah) and reference ranibizumab in patients with diabetic macular edema — Europe PMC PMID:41743118

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41743118
DOI
10.3389/fphar.2026.1773081
License (as archived)
solo-consultazione
Archived
2026-11-05T23:31:23.902Z
SHA-256 of the archived text
f7ea8fdbaf44bcba0eaa70e549e85d01c9706dbc3a5fdb47c4ea67fbacfafd23
Stable URL of this page
https://metraipolis.com/documento/dc_b2f0e60b80fb

How to cite

A comparative study on the efficacy and safety of biosimilar (Rimmyrah) and reference ranibizumab in patients with diabetic macular edema — Europe PMC PMID:41743118 — Europe PMC (en), https://europepmc.org/article/MED/41743118 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_b2f0e60b80fb (Metraipolis archive dc_b2f0e60b80fb, sha256 f7ea8fdbaf44bcba0eaa70e549e85d01c9706dbc3a5fdb47c4ea67fbacfafd23)
BibTeX
@misc{dcb2f0e60b80fb,
  title = {A comparative study on the efficacy and safety of biosimilar (Rimmyrah) and reference ranibizumab in patients with diabetic macular edema — Europe PMC PMID:41743118},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41743118},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_b2f0e60b80fb; sha256 f7ea8fdbaf44bcba0eaa70e549e85d01c9706dbc3a5fdb47c4ea67fbacfafd23},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41743118. Agents can read the archived copy with the MCP tool read_document.